# A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

> **NCT06903702** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 100 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine (AZA)
- **DRUG:** Venetoclax
- **PROCEDURE:** Allogeneic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT06903702
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-04
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-08-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06903702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06903702, "A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06903702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*